Boston Scientific Corp (BSX)vsElectrocore LLC (ECOR)
BSX
Boston Scientific Corp
$42.98
-0.28%
HEALTHCARE · Cap: $62.29B
ECOR
Electrocore LLC
$9.62
+4.68%
HEALTHCARE · Cap: $81.59M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 56698% more annual revenue ($21.00B vs $36.97M). BSX leads profitability with a 17.5% profit margin vs -40.0%. BSX earns a higher WallStSmart Score of 72/100 (B).
BSX
Strong Buy72
out of 100
Grade: B
ECOR
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-10.0%
Fair Value
$39.07
Current Price
$42.98
$3.91 premium
Margin of Safety
+82.8%
Fair Value
$31.76
Current Price
$9.62
$22.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.3B in free cash flow
Conservative balance sheet, low leverage
Revenue surging 28.0% year-over-year
Areas to Watch
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -478.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.60 suggests the stock is reasonably priced for its growth.
Bull Case : ECOR
The strongest argument for ECOR centers on Debt/Equity, Revenue Growth. Revenue growth of 28.0% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are Altman Z-Score.
Bear Case : ECOR
The primary concerns for ECOR are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
BSX profiles as a mature stock while ECOR is a growth play — different risk/reward profiles.
ECOR carries more volatility with a beta of 0.94 — expect wider price swings.
ECOR is growing revenue faster at 28.0% — sustainability is the question.
BSX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (72/100 vs 24/100), backed by strong 17.5% margins. ECOR offers better value entry with a 82.8% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Electrocore LLC
HEALTHCARE · MEDICAL DEVICES · USA
electroCore, Inc., a commercial-stage medical device company, is dedicated to the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is headquartered in Rockaway, New Jersey.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?